Daily Endocrinology Research Analysis
Analyzed 120 papers and selected 3 impactful papers.
Summary
Analyzed 120 papers and selected 3 impactful articles.
Selected Articles
1. Estimated Glomerular Filtration Rate Change and Heart Failure Events With GLP-1 Receptor Agonists: A Meta-Analysis and Meta-Regression of Randomised Controlled Trials.
Across 11 large randomized trials (90,867 participants), GLP-1RAs reduced clinical heart failure events. Trial-level meta-regression showed that greater annualized improvements in eGFR were associated with larger reductions in heart failure risk, suggesting a kidney–heart mechanistic link beyond glucose or blood pressure effects.
Impact: Identifies eGFR change as a potential surrogate of heart failure benefit with GLP-1RAs across rigorous RCTs, informing both trial design and clinical monitoring.
Clinical Implications: When prescribing GLP-1RAs, serial eGFR assessment may help gauge heart failure benefit alongside glycemic and blood pressure control, potentially guiding therapy intensification and risk communication.
Key Findings
- GLP-1RAs reduced clinical heart failure events overall (HR 0.86, 95% CI 0.80–0.93).
- Mixed-effects meta-regression linked greater annualized eGFR improvement with larger heart failure risk reduction across trials.
- Associations appeared independent of weight, systolic blood pressure, and heart rate changes at the trial level.
Methodological Strengths
- Meta-analysis of large randomized, placebo-controlled trials with prespecified outcomes
- Use of mixed-effects meta-regression to interrogate mechanistic surrogates (annualized eGFR change)
Limitations
- Trial-level (ecological) meta-regression cannot establish patient-level causality
- Heterogeneity in trial populations and background therapies may confound observed associations
Future Directions: Individual participant data meta-analyses and prospective trials should validate eGFR change as a surrogate for heart failure outcomes with GLP-1RAs and define thresholds for clinical decision-making.
AIMS: To examine whether on-treatment changes in kidney function and cardiometabolic markers are associated with the magnitude of heart failure (HF) risk reduction across large-scale trials of glucagon-like peptide-1 receptor agonists (GLP-1RAs). MATERIALS AND METHODS: We searched PubMed and Embase from inception to 29 January 2026 for randomised, placebo-controlled GLP-1RA trials enrolling ≥ 1000 adults with type 2 diabetes and/or overweight or obesity and a follow-up of at least one year. The primary outcome was clinical HF events (hos
2. 3D volume growth rate may open new perspectives for the classification of aggressive pituitary adenomas.
Quantitative 3D volume growth rate (3DVGR) stratified pituitary adenomas into progression risk groups with striking discrimination (AUC 0.992). Thresholds of <50%, 50–79%, and ≥80% per year mapped to median PFS of 99, 39, and 7 months, respectively; 3DVGR ≥50% independently predicted early progression, outperforming proliferative histology alone.
Impact: Introduces a reproducible imaging biomarker that refines aggressiveness classification beyond histology and directly informs surveillance intensity and adjuvant treatment decisions.
Clinical Implications: Incorporating 3DVGR thresholds into postoperative risk assessment can prioritize closer surveillance and earlier multimodal therapy for tumors with ≥50%/year growth, especially when combined with Ki-67 ≥8%.
Key Findings
- Median 3DVGR was 21.2%/year in nonproliferative vs 60.2%/year in proliferative adenomas (P < .0001).
- ROC analysis (AUC 0.992) defined 3DVGR groups: <50%, 50–<80%, ≥80%/year with median PFS 99.0, 39.0, and 7.0 months, respectively.
- In multivariate analysis, only 3DVGR ≥50%/year predicted early progression; proliferative status lost significance.
- Combining 3DVGR (≥80% or 50–<80%) with Ki-67 ≥8% identified a very high-risk subset (median PFS 8.5 months vs 64 months).
Methodological Strengths
- Quantitative MRI-based growth metric with ROC-derived risk thresholds
- Multivariate analyses linking imaging biomarker to progression-free survival
Limitations
- Retrospective single-center selection may limit generalizability
- External validation and standardized acquisition protocols are needed
Future Directions: Prospective, multicenter validation of 3DVGR thresholds and integration with molecular markers should inform a combined clinico-radiomic risk model for pituitary adenomas.
PURPOSE: The 2022 WHO classification states no histological grading exists to assess pituitary adenoma (PA) aggressiveness. The European Society of Endocrinology refers to the term "unusually rapid growth rate" when defining an aggressive PA. This study aimed to evaluate three-dimensional volume growth rate (3DVGR) in multiple PAs and correlate it with tumor progression and histopathology. METHODS: Patients with growing or proliferative PAs who underwent surgery were retrospectively selected. Gadolinium-enhanced 3D T1-we
3. Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis.
In 46 observational cohorts (N=7,124,845), a Bayesian network meta-analysis found class-specific hepatic associations: thiazolidinediones were least associated with hepatocellular carcinoma, GLP-1RAs with decompensation events, and SGLT2 inhibitors with cirrhosis and liver-related mortality. Findings underscore heterogeneity of liver risk reduction across antihyperglycemic classes.
Impact: Provides the most comprehensive comparative synthesis to date of antidiabetic drug classes and major liver outcomes, guiding hepatometabolic therapy selection and trial prioritization.
Clinical Implications: In T2DM with high hepatic risk, GLP-1RAs may be prioritized for decompensation risk, SGLT2 inhibitors for cirrhosis and liver-related mortality, and thiazolidinediones for HCC risk—but decisions must weigh class-specific adverse effects and the observational nature of the evidence.
Key Findings
- 46 observational studies (N=7,124,845) synthesized via three-level Bayesian network meta-analysis.
- Thiazolidinediones had the lowest association with hepatocellular carcinoma compared with DPP-4 inhibitors, GLP-1RAs, insulin, and sulfonylureas.
- GLP-1RAs were least associated with decompensation; SGLT2 inhibitors were least associated with cirrhosis and had the lowest liver-related mortality.
- All included studies were observational, precluding causal inference.
Methodological Strengths
- Very large cumulative sample with class-wide comparisons via Bayesian NMA
- Random-effects modeling at study and database levels with SUCRA ranking
Limitations
- Observational design vulnerable to confounding by indication and residual bias
- Heterogeneous definitions and adjudication of liver outcomes across databases
Future Directions: Randomized head-to-head trials in T2DM with MASLD/cirrhosis are needed to test class-specific hepatic benefits and validate signals seen in real-world evidence.
BACKGROUND: Type 2 diabetes mellitus (T2DM) amplifies liver disease burden, yet the comparative hepatic effects of antidiabetic drugs remain poorly defined. PURPOSE: To compare associations between antidiabetic drug classes and major adverse liver outcomes (MALOs) in adults with T2DM. DATA SOURCES: PubMed, EMBASE, and Cochrane Central Register of Controlled Trials were searched from December 1946 through 23 August 2025. STUDY SELECTION: Studies enrolling adults with T2DM that evaluated associations between antidiabetic drug classes with regard to MALOs were included. DATA EXTRACTION: Data were extracted on study